Eli Lil­ly an­tic­i­pates rev­enue boost in 2023 as it pre­pares to launch slate of new drugs

Eli Lil­ly ex­ec­u­tives are bull­ish on its prospects for next year as the In­di­anapo­lis phar­ma lifts the cov­er on its 2023 fi­nan­cial guid­ance.

Rev­enues are ex­pect­ed to land be­tween $30.3 bil­lion and $30.8 bil­lion next year, Lil­ly said on Tues­day, a bump over its ex­pect­ed 2022 rev­enue be­tween $28.5 bil­lion and $29 bil­lion as re­port­ed in the third quar­ter. Lil­ly at­trib­uted the 2023 gains to “vol­ume-based rev­enue growth” for ex­ist­ing prod­ucts, along with up to four pos­si­ble launch­es for do­nanemab, pir­to­bru­ti­nib, le­brik­izum­ab and mirik­izum­ab. Among those, key Phase III read­outs are ex­pect­ed for do­nanemab in ear­ly Alzheimer’s and mirik­izum­ab in Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER